A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician.

Trial Profile

A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Escherichia coli vaccine (Primary)
  • Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
  • Focus Pharmacodynamics
  • Sponsors Intercell USA; Valneva USA
  • Most Recent Events

    • 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
    • 09 Sep 2008 Planned end date changed from 1 Jun 2008 to 1 Aug 2008, according to ClinicalTrials.gov.
    • 08 Sep 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top